Diffuse Idiopathic Skeletal Hyperostosis (DISH) Study Group

Slides:



Advertisements
Similar presentations
What features of inflammatory arthritis aid a rheumatology nurse specialist in diagnosing inflammatory arthritis? G. Gormley 1*, K. Steele 1, D. Gilliland.
Advertisements

Wrap-Up and Post Course Self Assessment Dr. Diane Lacaille.
Diagnostic Method Diagnosis Diagnosis means `through knowledge` and entails acquisition of data about the patient and their complaints using the senses:
Achy shoulders and a very high CRP Sarah Tansley Rheumatology, Clinical Fellow.
Inflammatory Low Back Pain
PROactive Physical Activity as a Crucial Patient Reported Outcome in COPD
Discuss validity and reliability of diagnosis
Copyright restrictions may apply Sensitivity and Specificity of a Point-of-Care Matrix Metalloproteinase 9 Immunoassay for Diagnosing Inflammation Related.
Carpal Tunnel Syndrome A New Care Pathway. Format Introduction (5mins) SL Current Rheumatology issues (15mins) AY Current Orthopaedic Issues (10mins)
Psychopathology Introduction. ource/view.php?id=6874http://vle.ccs.northants.sch.uk/mod/res ource/view.php?id=6874.
Division of Population Health Sciences Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn Diagnostic accuracy of the ID-Migraine:
Consultant Rheumatologist
Standard 2. Diagnosis The registered nurse analyzes the assessment data to determine the diagnosis or the issues.
KEVIN W. POWERS, Ph.D. CREIGHTON UNIVERSITY ACADEMIC SUCCESS PSYCHOLOGIST CENTER FOR HEALTH AND COUNSELING Student Assessment & The ADA.
What we are learning about Alzheimer’s disease genetics Bryan J. Traynor.
2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative An.
Serum Dickkopf-1 ( DKK-1) and Arthritis in Systemic Lupus Erythematosus Patients S. I. Nasef, H. H. Omar Samah Ismail Nasef MD, MRCP Rheumatology UK Lecturer.
Clinical guidelines.
EULAR Study Group on Microcirculation in Rheumatic Diseases (SG MC/RD)
Background Hand injury is a common presentation at A&E in the UK
How to Use the Nursing Diagnosis Handbook: A Guide to Planning Care
EULAR Study Group on Systemic Lupus Erythematosus (SLE) Dimitrios T
ACOEM Council on Education and Academic Affairs
Thomas Parker, Scott Patrick, D.J. Panu
FINAL Recommendations
EULAR nurses study group for REsearch and STrategy (REST)
The Nursing Process and Pharmacology Jeanelle F. Jimenez RN, BSN, CCRN
EULAR Study Group on Microcirculation in Rheumatic Diseases (SG MC/RD) V. Smith*1, A. Herrick2, A. Sulli3 and M. Cutolo3 1Ghent University Hospital, University.
Diagnosing Rheumatoid Arthritis Early
Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.
Hunter Syndrome: Why We Need to Diagnose and Treat Early
EULAR Study Group on Systemic Lupus Erythematosus (SLE) Dimitrios T
Respiratory MCNs - Interstitial lung diseases
Wrap-Up and Post Course Self Assessment
European League Against Rheumatism/American College of Rheumatology classification criteria probability of having idiopathic inflammatory myopathies (IIMs)
Algorithm for the diagnosis of CF starting with the CFTR DNA test.
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Year 10 Subject Selection – Psychology
EULAR Study Group on Registers and Observational Drug Studies (RODS)
Assessment of BPSD Rajesh Tampi , MD Professor of Psychiatry
Percentage of patients achieving EULAR response
Classification tree for subgroups of idiopathic inflammatory myopathies (IIMs). Classification tree for subgroups of idiopathic inflammatory myopathies.
ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.
Prevalence of any pathological finding for inflammation (intratendinous or peritendinous inflammatory signal, bone marrow oedema at the painful sites)
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI
Assignment 2 Learning Aim D: Individual Treatment Plan
Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.
Criteria for Early-Phase Diffuse Idiopathic Skeletal Hyperostosis: Development and Validation Early DISH may include at least three adjacent segments were.
Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.
Flow chart based on the results of the Consensus Conference.
EULAR-defined characteristics describing arthralgia at risk for RA
Clinical response in patients with early and established RA at month 24. *p
Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.
Management of patients with obesity hypoventilation syndrome (OHS) from diagnosis to integrated care to modify health trajectories. Management of patients.
Merging the Art and Science of Managing nOH in Clinical Practice
ACR20/50/70 response rates at week 24 (TP1 per-protocol set).
Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia.
Synovial Biopsy in Patients with UPIA
The Study Group aims to:
Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI
Acute Phase Reactants in Patients with UPIA
EULAR Study Group on SLE
Projects with publication Courses, meetings and presentations in 2018
Flowchart of literature revision to identify current available clinical practice guidelines (CPGs) specifically addressed to Ehlers-Danlos Syndromes (EDS)
Classification tree with the selected characteristics.
Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.
Slide 1: Target population/question
Slide 1: Target population/question
EULAR Recommendation/Points to Consider Slide set template Slide set should, if possible, not exceed 20 Slides Please submit slide set along with final.
Presentation transcript:

Diffuse Idiopathic Skeletal Hyperostosis (DISH) Study Group The Study Group aims to: organize and present a systematic literature review of the currently existing criteria for diagnosing DISH in daily practice assess the value of clinical symptoms and objective findings (incl. imaging and laboratory markers) and producing a diagnostic algorithm for patients who are clinically suspicious for DISH organize long-term projects with patients diagnosed with DISH in order to document the natural process of the disease, including current treatment practices identify factors that may be able to predict the development of the typical structural bony changes leading to functional disability and pain in patients with metabolic syndrome investigate the pathogenetic pathways that lead to new bone formation investigate if the disease is conditioned by a genetic predisposition. Up to now, the group has set up a research agenda covering all aspects of the Group aims. The projects are ongoing / being planned Publications: Kuperus J et al, Classification criteria for diffuse idiopathic skeletal hyperostosis: a lack of consensus, Rheumatology 2017 Mader R, et al, Difuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next., RMD Open 2017 The EULAR DISH Study group consists of rheumatologists, radiologists, geneticists, orthopaedic surgeons and patients who have scientific interest in the diagnosis and natural course of DISH The aim is investigate the clinical presentation and necessary diagnostic procedures for ensuring the diagnosis of DISH. So far, such information does not exist because of unclear clinical symptoms of this diagnosis. Furthermore, there is no consensus of which diagnostic criteria are best suitable for DISH for differentiate it from other inflammatory hyperproliferative rheumatic diseases. Task Force / Committee: X. Baraliakos, R. Mader, J.J.Verlaan, I. Eshed, J. Bruges-Armas, P. Sarzi Puttini, F. Atzeni, D. Buskila, I. Novofastovski, K. de Vlaam, J. Kuperus Points of contact: xenofon.baraliakos@elisabethgruppe.de. / rmader@012.net.il